Myelofibrosis is a rare blood cancer, in which fibrous scar tissue replace bone marrow. Myelofibrosis is considered as a form of lukemia. The symptoms of the disease comprise fatigue, anemia, enlarged spleen and weakness. Myelofibrosis is often observed in people over the age of 50 years. It is categorised into primary and secondary myelofibrosis. Treatment options for the disease are rare. However, in 2011, the U.S. FDA grated approval to Jakafi (Ruxolitinib), the only product approved by FDA for myelofibrosis treatment.
Frequent FDA approvals of pipeline drugs, large investment in R&D, large number of patients with myelofibrosis, favourable reimbursement policies are expected to boost growth of the global myelofibrosis treatment market.
Increasing development in myelofibrosis treatment is also expected to propel growth of the global myelofibrosis treatment market. For instance, Gilead Sciences developed CYT387 or Momelotinib, for treatment of primary myelofibrosis. Similarly, Incyte Corporation developed a current drug, ruxolitinib, a substitute dosing strategy for myelofibrosis patients.
Moreover, factors such as change in lifestyle, growing cases of genetic disorders, and rising population with smoking habits are expected to propel growth of the myelofibrosis treatment market.
High cost of treatment and lack of awareness of new therapies are expected to hamper growth of the global myelofibrosis treatment market.
The global myelofibrosis treatment market is divided into diagnosis, treatment, end user, and geography.
Gene Mutation Analysis
Bone Marrow Biopsy
Stem Cell Transplant
By end user:
Bone Marrow Transplant Centers
The global myelofibrosis treatment market is regionally divided into North America, Europe, Latin America, Middle East, Asia Pacific, and Africa.
North America is expected to witness substantial growth in the global myelofibrosis treatment market due to increasing cases of diseases, rising awareness, encouraging reimbursement policies, and high expenditure in healthcare. In 2016, the American Society of Hematology reported around 20,000 Americans are affected by myelofibrosis, which is a highly fatal blood cancer.
Asia Pacific is expected to witness significant growth in the global market of myelofibrosis treatment, attributed to increasing geriatric population, growing disposable incomes and advanced healthcare facilities.
Major players active in the global myelofibrosis treatment market are Eli Lilly, Merck & Co., Celgene, Bristol-Myers Squibb, Gilead Sciences, Novartis, Roche, Amgen, and Incyte Corporation.
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Myelofibrosis Treatment Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Myelofibrosis Treatment Industry Impact
Chapter 2 Global Myelofibrosis Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Myelofibrosis Treatment (Volume and Value) by Type
2.3 Global Myelofibrosis Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Myelofibrosis Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Myelofibrosis Treatment Market Analysis
Chapter 6 East Asia Myelofibrosis Treatment Market Analysis
Chapter 7 Europe Myelofibrosis Treatment Market Analysis
Chapter 8 South Asia Myelofibrosis Treatment Market Analysis
Chapter 9 Southeast Asia Myelofibrosis Treatment Market Analysis
Chapter 10 Middle East Myelofibrosis Treatment Market Analysis
Chapter 11 Africa Myelofibrosis Treatment Market Analysis
Chapter 12 Oceania Myelofibrosis Treatment Market Analysis
Chapter 13 South America Myelofibrosis Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Myelofibrosis Treatment Business
Chapter 15 Global Myelofibrosis Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027